Research graph
References from A signaling-optimized TIGIT chimeric switch receptor promotes metabolic fitness and antitumor efficacy of TCR/CAR T cells. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1126/sciadv.adf3700
10.1126/sciadv.adf3700 · External reference
10.1038/s41392-025-02269-w
10.1038/s41392-025-02269-w · External reference
Beyond the blood: expanding CAR T cell therapy to solid tumors
10.1038/s41587-024-02446-2 · 2025 · External reference
10.1016/j.coi.2012.12.003
10.1016/j.coi.2012.12.003 · External reference
CTLA-4 Overexpression Inhibits T Cell Responses through a CD28-B7-Dependent Mechanism
10.4049/jimmunol.177.2.1052 · 2006 · External reference
10.1126/science.aaf1292
10.1126/science.aaf1292 · External reference
10.1172/jci80445
10.1172/jci80445 · External reference
10.1186/s13045-018-0578-4
10.1186/s13045-018-0578-4 · External reference
Chimeric Switch Receptor: Switching for Improved Adoptive T-Cell Therapy Against Cancers
10.2217/imt-2017-0103 · 2017 · External reference
10.1126/science.abq6990
10.1126/science.abq6990 · External reference
10.1126/science.aar6711
10.1126/science.aar6711 · External reference
10.1056/nejmoa1707447
10.1056/nejmoa1707447 · External reference
10.1158/0008-5472.can-16-1922
10.1158/0008-5472.can-16-1922 · External reference
10.1158/0008-5472.can-15-2524
10.1158/0008-5472.can-15-2524 · External reference
10.1186/s13045-021-01044-y
10.1186/s13045-021-01044-y · External reference
10.1136/jitc-2021-003176
10.1136/jitc-2021-003176 · External reference
A TIGIT-based chimeric co-stimulatory switch receptor improves T-cell anti-tumor function
10.1186/s40425-019-0721-y · 2019 · External reference
TIGIT can inhibit T cell activation via ligation-induced nanoclusters, independent of CD226 co-stimulation
10.1038/s41467-023-40755-3 · 2023 · External reference
Knockout of the inhibitory receptor TIGIT enhances the antitumor response of ex vivo expanded NK cells and prevents fratricide with therapeutic Fc-active TIGIT antibodies
10.1136/jitc-2023-007502 · 2023 · External reference
10.1016/j.celrep.2020.107892
10.1016/j.celrep.2020.107892 · External reference
Implication of TIGIT+ human memory B cells in immune regulation
10.1038/s41467-021-21413-y · 2021 · External reference
10.1016/j.ccell.2014.10.018
10.1016/j.ccell.2014.10.018 · External reference
10.1038/ni.1674
10.1038/ni.1674 · External reference
10.1111/cas.13324
10.1111/cas.13324 · External reference
10.1186/s13046-021-02053-y
10.1186/s13046-021-02053-y · External reference
10.1158/0008-5472.can-17-0381
10.1158/0008-5472.can-17-0381 · External reference
10.1182/blood-2018-01-825265
10.1182/blood-2018-01-825265 · External reference
10.1111/cei.13407
10.1111/cei.13407 · External reference
A Potent Tumor-Reactive p53-Specific Single-Chain TCR without On- or Off-Target Autoimmunity In Vivo
10.1016/j.ymthe.2018.11.006 · 2019 · External reference
10.1136/jitc-2020-001846
10.1136/jitc-2020-001846 · External reference
10.1007/978-1-4939-8885-3_7
10.1007/978-1-4939-8885-3_7 · 2019 · External reference
10.1038/nm.3838
10.1038/nm.3838 · External reference
10.1172/jci133215
10.1172/jci133215 · External reference
10.1038/s41590-020-0793-3
10.1038/s41590-020-0793-3 · External reference
10.1038/s41590-020-0725-2
10.1038/s41590-020-0725-2 · External reference
10.1038/s41467-023-42634-3
10.1038/s41467-023-42634-3 · External reference
CRISPR/Cas9 TCR-Edited NKp30 CAR T Cells Exhibit Superior Anti-Tumor Immunity to B7H6-Expressing Leukemia and Melanoma
10.3390/ijms26178235 · 2025 · External reference
10.1146/annurev-pathol-042020-042741
10.1146/annurev-pathol-042020-042741 · External reference
10.3389/fimmu.2025.1662238
10.3389/fimmu.2025.1662238 · External reference
10.1016/j.molimm.2012.03.023
10.1016/j.molimm.2012.03.023 · External reference
10.1093/jnci/djv146
10.1093/jnci/djv146 · External reference
10.1038/s41392-022-01198-2
10.1038/s41392-022-01198-2 · External reference
10.1182/blood-2011-09-380519
10.1182/blood-2011-09-380519 · External reference
10.1016/j.xcrm.2024.101421
10.1016/j.xcrm.2024.101421 · External reference
10.3389/fimmu.2022.845499
10.3389/fimmu.2022.845499 · External reference
10.1038/s41571-021-00552-7
10.1038/s41571-021-00552-7 · External reference
10.1080/2162402x.2023.2265703
10.1080/2162402x.2023.2265703 · External reference
Cutting Edge: Persistence of Transferred Lymphocyte Clonotypes Correlates with Cancer Regression in Patients Receiving Cell Transfer Therapy
10.4049/jimmunol.173.12.7125 · 2004 · External reference
CAR T-Cell Persistence Correlates with Improved Outcome in Patients with B-Cell Lymphoma
10.3390/ijms24065688 · 2023 · External reference
10.1073/pnas.1113748109
10.1073/pnas.1113748109 · External reference
T-Cell Therapy Using Interleukin-21–Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression
10.1200/jco.2015.65.5142 · 2016 · External reference
10.1016/j.immuni.2016.02.023
10.1016/j.immuni.2016.02.023 · External reference
Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation
10.1172/jci.insight.96976 · 2018 · External reference
10.1073/pnas.0813101106
10.1073/pnas.0813101106 · External reference
10.1038/mt.2009.83
10.1038/mt.2009.83 · External reference
Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation
10.1172/jci.insight.96976 · 2018 · External reference
10.3389/fimmu.2021.642528
10.3389/fimmu.2021.642528 · External reference
Bioactivity and safety of chimeric switch receptor T cells in glioblastoma patients
10.2741/4772 · 2019 · External reference
Unresolved reference
External reference
10.1158/1078-0432.ccr-20-1457
10.1158/1078-0432.ccr-20-1457 · External reference
10.1385/1-59259-862-5:229
10.1385/1-59259-862-5:229 · 2004 · External reference
The mechanism of anti-Lyt-2 inhibition of antibody-directed lysis by cytotoxic T lymphocytes
10.4049/jimmunol.139.11.3590 · 1987 · External reference
